FDA loses power to block unapproved drugs sold as supplements

What it does

This bill amends the Federal Food, Drug, and Cosmetic Act to clarify when a drug ingredient can be added to dietary supplements without triggering FDA drug-approval requirements. It creates new exceptions allowing drugs in clinical trials (Phase 2/3) to be added to supplements if the trials have been inactive for 7+ years, or if the drug was marketed as a supplement before clinical testing began. It also shifts the burden of proof to the FDA to demonstrate a violation, and makes FDA warning letters immediately challengeable in court.

Why we flagged it

The bill's operative mechanism is to create exceptions to FDA's drug-preclusion rule, allowing pharmaceutical ingredients to be marketed as dietary supplements under conditions that bypass traditional drug-approval pathways. This is a regulatory carve-out favoring the supplement industry over FDA enforcement authority.

What the text implies

• The 7-year inactive-trial exception may allow sponsors to deliberately pause clinical trials to reset the clock, converting failed or stalled drug development into supplement ingredients without FDA approval.
• Shifting burden of proof to FDA in court challenges means the agency must affirmatively prove harm or violation, rather than requiring supplement makers to prove safety—a reversal of the traditional FDA enforcement model.
• The 'marketed as supplement before drug development began' exception creates a loophole for substances that were sold as supplements, then later studied as drugs, then returned to supplements—potentially circumventing the entire drug-approval process.
• Immediate judicial review of FDA warning letters may paralyze enforcement by forcing the agency to litigate every supplement-drug boundary case before it can take action, creating delay and uncertainty.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands consumer access to supplement-drug combinations and reduces regulatory barriers, which may lower costs and increase choice; however, it simultaneously weakens FDA's ability to prevent unapproved drugs from entering the supplement market under the guise of dietary supplements, potentially exposing consumers to inadequately tested substances marketed without drug-level safety review.

Who stands to gain

• dietary supplement manufacturers
• supplement ingredient suppliers
• contract research organizations (CROs) managing clinical trials

Named in the bill

FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, Section 301(ll), Section 413A, Section 201(ff), Phase 2 and Phase 3 clinical investigations, dietary supplements, approved drugs

Where it stands

• Sep 10, 2026 — Introduced · Congress.gov: “Introduced in House”
• Sep 10, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.